Y-mAbs Therapeutics,
Y-mAbs Therapeutics, Inc. Shareholder Alert: Kaplan Fox Investigates Potential Securities Fraud
November 04, 2022 09:00 ET | Kaplan Fox & Kilsheimer LLP
NEW YORK, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the...
Y-mAbs Therapeutics,
Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) Investor Alert: Kaplan Fox Investigates Potential Securities Fraud
October 31, 2022 10:13 ET | Kaplan Fox & Kilsheimer LLP
NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the...